AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q2 2018 Earnings Presentation

36 slides from AMAG Pharmaceuticals's earnings presentation, Aug 2, 2018

  1. Slide 1: Q2-2018 Financial Results

    Q2-2018 Financial Results August 2, 2018 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, the

  3. Slide 3: Agenda

    Agenda 1 Q2-2018 Highlights 2 Product Portfolio Update 3 Q2-2018 Financial Overview 4 Key Priorities and Closing Remarks 5 Q&A © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 3

  4. Slide 4: Strong Execution: Q2-2018 Highlights

    Strong Execution Total Revenue ($M) Q2-2018 Highlights $176.3 Announced sale of CBR $158.4 CBR Underscores focus on Strengthens CBR development and balance $146.3 12% commercialization of sheet $130.4 pharmaceutical products FDA accepts NDA for bremelanotide with PDUFA date of 3/23/19 Strong Q2-2018

  5. Slide 5: Growing Innovative Pipeline

    Growing Innovative Pipeline Approved/ PHASE 1 PHASE 2 PHASE 3 Regulatory Review Marketed Treatment of iron deficiency anemia Treatment to reduce recurrent preterm birth in certain at-risk women Treatment for moderate to severe dyspareunia (pain during sex) in postmenopausal women 1 Treatment of low

  6. Slide 6: Severe Preeclampsia Program

    Severe Preeclampsia Program1 Significant unmet medical need with large market opportunity • Leading cause of maternal morbidity and mortality and adverse neonatal outcomes – Condition characterized by hypertension and end organ damage in pregnant women – Preeclampsia affects 136,000 pregnant women i

  7. Slide 7: Makena Feraheme Intrarosa Bremelanotide

    Makena® Feraheme® Intrarosa® Bremelanotide 7

  8. Slide 8: Makena: Record Quarterly Revenue and Market Share

    Makena: Record Quarterly Revenue and Market Share Market Share1 Makena Revenue ($M) June 30, 2018 $105.2 $102.7 Off Guidance2 30% Makena 51% Compounded Hydroxy- progesterone Caproate 19% Q2-2017 Q2-2018 1 Company estimates Makena market share based on distributor dispensing data and all other market

  9. Slide 9: Optimize Makena Franchise Performance & Sustainability

    Optimize Makena Franchise Performance & Sustainability Protect the Brand Share in Generic Market • Convert usage to Makena SC auto-injector • First generic ANDA approved in June for – ~60% Makena Care Connection (MCC) enrollments are for single-dose intramuscular Makena SC auto-injector hydroxyproge

  10. Slide 10: Positive Physician Feedback Regarding Makena SC Auto-injector

    Positive Physician Feedback Regarding Makena Subcutaneous (SC) Auto-injector1 Perceptions of Makena SC Auto-injector Benefits of Makena SC Auto-injector Benefits Over Intramuscular (% Selecting) (% mentioned, unaided) 70% Ease of use / ease of administration 22% 1% (pre-loaded, single-dose) 34% Admi

  11. Slide 11: Makena Feraheme Intrarosa Bremelanotide

    Makena® Feraheme® Intrarosa® Bremelanotide 11

  12. Slide 12: Record Quarterly Feraheme Revenue and Market Share

    Record Quarterly Feraheme Revenue and Market Share Feraheme gained >5 market share points over Q1-2018 IV Iron Deficiency Anemia (IDA) Feraheme Revenue1 ($M) Quarterly Market Share by Product2 $37.7 Q2-2018 0.6% Feraheme $27.5 37% 11.7% Injectafer 36.6% Venofer 16.3% INFeD 34.8% Ferrlecit/Nulecit Q2

  13. Slide 13: Growing Share through Clinical Differentiation and New Broad Label

    Growing Share through Clinical Differentiation and New Broad Label Feraheme monthly market share1 SALINE SHORTAGE IMPACT 17.1% 16.2% 15.4% Indicators of Launch Success 12.3% 11.8% Early converted Higher utilization Growing monthly 10.7% accounts 10.2% of Feraheme in number of producing accounts orde

  14. Slide 14: IV Iron Market Represents Small Subset of IDA Patients

    IV Iron Market Represents Small Subset of Patients Who Suffer from IDA 4.5M total U.S. patients diagnosed with iron deficiency anemia1 Diagnosed IDA Patients • Under the care of other physician specialists, including in women’s health, where AMAG has a strong commercial presence 700,000 IV iron pati

  15. Slide 15: Makena Feraheme Intrarosa Bremelanotide

    Makena® Feraheme® Intrarosa® Bremelanotide 15

  16. Slide 16: Intrarosa is Differentiated from Estrogen Therapies

    Intrarosa is Differentiated from Estrogen Therapies Non-estrogen treatment1  Differentiated MOA1   Unique safety profile (no boxed warning) 1 Intrarosa is converted by enzymes in the body into androgens and estrogens, though the mechanism of action is not fully established. WOMEN’S HEALTH: INTRAR

  17. Slide 17: Significant Momentum with HCPs Continues

    Significant Momentum with HCPs Continues At 3/31/18 At 6/30/18 TRx’s written since launch1 ~50,000 ~93,000 HCP prescribers since launch1 ~6,600 ~9,100 Total week ending market share1 2.8% 3.8% Commercial lives covered (unrestricted)2 74% 75% CMS clarified that drugs for the treatment of Medicare Par

  18. Slide 18: Intrarosa HCP Prescribing and Market Share Continue to Increase

    Intrarosa HCP Prescribing and Market Share Continue to Increase Rx Volume1 • High level of sales force HCP engagement 4,500 – Averaged 2,000 weekly prescribers in Q2, a 41% increase 4,000 over Q1 3,500 – ~200 speaker programs held in Q2 3,000 • Intrarosa NRx market share continues to grow: 2,500 – 5

  19. Slide 19: Commercial Copay Savings Program

    Commercial Copay Savings Program Removing cost as a barrier and driving persistency • Comprehensive commercial copay savings program – $0 copay first month on therapy (regardless of formulary access) – Refill copays are no greater than $25 (regardless of formulary access) • Copay card driving high g

  20. Slide 20: 90% of Women with Dyspareunia Not on Prescription Therapy

    90% of Women with Dyspareunia Not on Prescription Therapy 20M women in U.S. suffer from dyspareunia, a symptom of VVA1 ~1.7M2 18M Currently on Rx U.S. women with dyspareunia not on prescription therapy2 estrogen therapy New potential patients represent a market opportunity of ~$14B/year4 #1 reason w

  21. Slide 21: Key Intrarosa Growth Drivers

    Key Intrarosa Growth Drivers Accessing the 90% of women who are not being treated with Rx Branded consumer campaign resulting 5 in patients asking for Intrarosa Increase HCP prescribing and make Intrarosa the 1st choice treatment 4 3 Educate with unbranded condition awareness campaign Create afforda

  22. Slide 22: Coming Soon: Unbranded and Branded Consumer Campaigns

    Coming Soon: Unbranded and Branded Consumer Campaigns PHASE 1: I N MARKET NOW PHASE 2: COMING SOON Copay Registration on Intrarosa.com Paid Search Campaign 1,400+ copay registrations Updated Intrarosa.com and media campaign 35,000+ visits to Intrarosa.com to date (730 redeemed) to date Robust media

  23. Slide 23: Makena Feraheme Intrarosa Bremelanotide

    Makena® Feraheme® Intrarosa® Bremelanotide 23

  24. Slide 24: Significant Market Opportunity in Area of High Unmet Need

    Significant Market Opportunity in Area of High Unmet Need 1 Bremelanotide Overview Self-administered auto-injector PEN NOVEL mechanism of action: used in ANTICIPATION melanocortin receptor agonist (MCR4) of sexual activity TWO Phase 3 studies met co-primary, pre-specified endpoints on desire and dis

  25. Slide 25: Financial Overview

    Financial Overview 25

  26. Slide 26: Divestiture of Cord Blood Registry

    Divestiture of Cord Blood Registry • $530M all-cash sale – Announced June 15, 2018; expected to close mid-August 2018 – Majority of net proceeds expected to be used to retire $475M Senior Notes • Debt repayment will align balance sheet with long-term growth strategy – Focus on investing and growing

  27. Slide 27: Strong Financial Results While Investing in the Future

    Strong Financial Results While Investing in the Future GAAP product revenue and operating income from continuing operations ($M)1 $146.3 $3.2 $130.4 12% $37.8  $27.7 5% Intrarosa Revenue $102.7 $105.2 Feraheme/MuGard Revenue Makena Revenue $41.9 GAAP Operating Income $3.3 Q2-2017 Q2-2018 1 Excludes

  28. Slide 28: Strong Financial Results: Product Revenue and Adjusted EBITDA

    Strong Financial Results While Investing in the Future Product revenue and non-GAAP adjusted EBITDA from continuing operations ($M)1 $146.3 $3.2 $130.4 12% $37.8 $27.7 Intrarosa Revenue $102.7 $105.2 Feraheme/MuGard Revenue $60.6 Makena Revenue $41.4 Adjusted EBITDA Q2-2017 Q2-2018 1 See slide 34 fo

  29. Slide 29: 2018 Financial Guidance: Adjusted for CBR Divestiture

    2018 Financial Guidance: Adjusted for CBR Divestiture and Revised Upward to Reflect Strong Execution 1 Remove CBR Guidance Increase Previous Expected Results Adjusted (pharmaceutical Updated ($M) Guidance2 (mid-Aug - Dec)3 Guidance products) 2018 Guidance Total revenue $540 - $580 $45 $495 - $535 $3

  30. Slide 30: Strengthening Balance Sheet

    Strengthening Balance Sheet ($M) 3/31/18 6/30/18 Cash, cash equivalents and investments $371 $4101 Principal debt outstanding: Convertible senior notes (2.5%) due 2019 $ 21 $ 21 Convertible senior notes (3.25%) due 2022 320 320 Senior notes (7.875%) due 20232 475 475 Total debt outstanding (current)

  31. Slide 31: 2018 Key Priorities

    2018 Key Priorities Progress to-date Bremelanotide Submit NDA in Q1-2018 Continue to drive HCP prescribing and initiate Intrarosa consumer campaign Launch subcutaneous auto-injector and drive Makena conversion Feraheme Launch broad IDA label and grow market share Cord Blood Registry Complete divesti

  32. Slide 32: Q&A

    Q&A © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 32

  33. Slide 33: Appendix

    Appendix 33

  34. Slide 34: Reconciliation of GAAP to Non-GAAP Financial Results

    Reconciliation of GAAP to Non-GAAP Financial Results1 ($M) Q2-2017 Q2-2018 GAAP operating income $3.3 $41.9 Depreciation and intangible asset amortization 25.4 62.1 Non-cash inventory step-up adjustments 0.2 1.0 Stock-based compensation 5.0 5.4 Adjustments to contingent consideration 1.7 (49.8) Acqu

  35. Slide 35: Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance

    Reconciliation of GAAP to Non-GAAP 2018 Financial Guidance Adjusted for CBR divestiture and revised upward to reflect expected pharmaceutical products results in 2H-2018 Remove CBR Previous Expected Results Adjusted Updated ($M) Guidance1 (mid-Aug – Dec)2 Guidance 2018 Guidance GAAP operating (loss)

  36. Slide 36: Q2-2018 Financial Results

    Q2-2018 Financial Results August 2, 2018 © 2018 AMAG Pharmaceuticals, Inc. All rights reserved 36

AMAG Pharmaceuticals — Q2 2018 Earnings Presentation on 6ix